Filter posts

Playing Detective With Checkpoint Therapies

Three words are on the lips of everyone following new developments in cancer therapies: checkpoint inhibitor …

San Francisco Chronicle: High Drug Co-Pays Deny Needed Treatments

Today, the San Francisco Chronicle published an op-ed that I wrote on the importance of …

Patients Suffering from Gaucher's Disease Deserve Better

Gaucher Disease is one of the over 6,000 rare diseases that affect patients worldwide, representing …

The New Republic: We are Entering the Age of Alzheimer’s

The New Republic this week published a lengthy, powerful piece by Kent Russell on Alzheimer’s. …

Fighting Ebola with Tobacco

Years in the making, the Ebola virus has recently erupted into a full blown health …

New study shows hepatitis C burden may ease in future

Anew study published in the Annals of Internal Medicine projects that the prevalence of hepatitis …

NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”

Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the …

Greenwood Highlights Need for Bold Action to Address Alzheimer's

Last week, Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), participated and …

Treating Hepatitis C: Too Costly Not to Act

Today, The Hill published an op-ed – Treating hepatitis C: Too costly not to act …

Partners for Healthy Dialogues: Letter to CMS

BIO, a member of Partners for Healthy Dialogues (P4HD), joined 25 medical societies and manufacturers in …